Greg Durm

801 posts

Greg Durm banner
Greg Durm

Greg Durm

@gdurm

Medical Oncologist in lung and head and neck cancer at Indiana University. Views are my own, unless they aren’t. Notre Dame, IUBB, Colts, and Reds. #LCSM

Indianapolis, Indiana Katılım Mayıs 2009
805 Takip Edilen591 Takipçiler
Greg Durm retweetledi
Laura Alder, MD
Laura Alder, MD@LauraAlderMD·
Terrific dinner with colleagues and friends before the @IndianaUniv Lung Cancer Symposium! Thanks to Dr Durm @gdurm and IU for the invitation and being such wonderful hosts! Looking forward to a day of learning tomorrow! #lcsm
Laura Alder, MD tweet media
English
0
3
21
749
Greg Durm retweetledi
Journal for ImmunoTherapy of Cancer
New #JITC article: Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081 bit.ly/44WS2xZ @gdurm @HirvaMamdani @SalmaJabbour1 @AparGanti @ShadiaJalal @DrJNaidoo @maryjofidlerMD @LealTiciana @DrLFeldman1
Journal for ImmunoTherapy of Cancer tweet media
English
0
7
23
1.5K
Greg Durm retweetledi
Nabil Adra
Nabil Adra@nabiladra·
Dr. Rebecca Hassoun presenting outcomes with salvage high dose chemo and transplant in relapsed GCT based on radiographic vs tumor marker progression @rebeccahassoun @IUCancerCenter @IUHemOnc
Nabil Adra tweet media
English
5
5
31
1.4K
Greg Durm retweetledi
ALK Positive
ALK Positive@ALKPositiveinc·
Why do people get ALK+ lung cancer? Why do some respond well to treatments and others less so? How can we better treat this disease? Lung cancer research is not just about answering these key questions, but about hope. It's why Dr @AngelQinMD believes #MoreResearchMoreLife.
ALK Positive tweet media
English
0
5
16
1.3K
Greg Durm retweetledi
Jarushka Naidoo
Jarushka Naidoo@DrJNaidoo·
ctDNA+ in consolidation IO trial (BTCRC 16-081) associates with outcomes in stage III unresectable NSCLC @JTOonline: - Tumor-informed ctDNA MRD analysis post CRT, C2D1 IO, & post 6m of IO - ctDNA+ assoc with ⬇️PFS at all timepts @OncoAlert @gdurm #LCSM jto.org/article/S1556-…
Dublin City, Ireland 🇮🇪 English
1
16
47
4.1K
Greg Durm retweetledi
Laura Vater, MD, MPH
Laura Vater, MD, MPH@doclauravater·
When you’re given a platform, you use it. Women: You can be great mothers and have successful careers. These are not mutually exclusive. Huge thanks to the UCSD Medical School graduating class for inviting me to speak this year! #womeninmedicine
English
13
47
373
41.8K
Greg Durm retweetledi
Noemi Reguart
Noemi Reguart@NReguart·
LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist
Noemi Reguart tweet mediaNoemi Reguart tweet mediaNoemi Reguart tweet mediaNoemi Reguart tweet media
English
1
53
121
17.2K
Greg Durm retweetledi
Sanjay Popat
Sanjay Popat@DrSanjayPopat·
Having seen LAURA, Dr Jayakrishnan presents retrospective ALK+ unresectsble st3 outcomes by consolidation Rx ost. Chemo-RT. ALK TKI rwPFS huge va no consolidation. Translates to OS benefit. Reinforces @LeciaSequist message that TKI consolidation important for AGA NSCLC #ASCO24
Sanjay Popat tweet mediaSanjay Popat tweet mediaSanjay Popat tweet mediaSanjay Popat tweet media
English
0
8
18
2K
Greg Durm retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
EVOKE-01 from #ASCO24 @JCO_ASCO. Phase III study of the Trop2 ADC sacituzumab govitecan vs docetaxel in NSCLC post chemo/IO. Did not meet OS endpoint (11.1 vs 9.8m, HR 0.84) but numeric improvement in squamous & non-sq. If nonresponsive to IO, OS HR 0.75 ascopubs.org/doi/10.1200/JC…
English
0
10
26
2.6K
Greg Durm retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
CROWN results from #ASCO24 @JCO_ASCO: phase III 1L lorlatinib vs crizotinib in #ALK NSCLC. With 5y median f/u, median PFS not reached. 5y PFS rate 60% with lorlatinib (8% with crizotinib), median time to intracranial progression NR vs 16.4m (HR 0.06). ascopubs.org/doi/10.1200/JC…
English
2
8
26
2.7K
Greg Durm retweetledi
Tom Newsom-Davis
Tom Newsom-Davis@tnewsomdavis·
KRYSTAL-12: Adagrasib vs Doce in KRAS G12C ✅ ⬆️ PFS HR=0.58 ✅ ⬆️ ORR 32 v 9% ✅ ⬆️ icRR 24 v 11% ❗️29% crossover ❗️⬆️ dose reduction, interruption + SAE 🤔 PFS benefit still modest 🤔 OS should be primary EP 🤔 CNS activity important 🤔 Toxicity significant #ASCO24 #LCSM
Tom Newsom-Davis tweet mediaTom Newsom-Davis tweet media
English
3
12
27
3.3K
Greg Durm retweetledi
Lauren Averett Byers, MD
Lauren Averett Byers, MD@LaurenByersMD·
POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. @MDAndersonNews Thank you to the study team and all of our investigators, patients and families. @ASCO #ASCO24
Lauren Averett Byers, MD tweet media
English
2
31
104
7K
Greg Durm retweetledi
Tom Newsom-Davis
Tom Newsom-Davis@tnewsomdavis·
Olomorasib (G12Ci) + Pembro, Ph1b ✅ ORR = 77% (1L), 40% (2L+) ✅ Irrespective of PD-L1 🔺 Gr3 AE = diarrhoea (13%), liver (6–8%), pruritis ❓Liver tox shortlived 🤔 Encouraging activity 🤔 Ph3 data needed 🤔 Severe tox in other immuno combos not seen here 👍 #ASCO24 #LCSM
Tom Newsom-Davis tweet mediaTom Newsom-Davis tweet mediaTom Newsom-Davis tweet media
English
0
8
15
2.3K
Greg Durm retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM astrazeneca.com/media-centre/p…
Stephen V Liu, MD tweet media
English
3
51
146
21.2K
Greg Durm retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Press release: phase III LAURA trial meets primary endpoint. Stage III #EGFR NSCLC post chemoradiation, indefinite osimertinib superior to placebo. No surprise - eager to see magnitude of benefit, patterns of relapse, OS trends, and crossover rate… astrazeneca.com/media-centre/p…
Bethesda, MD 🇺🇸 English
6
53
123
17.1K
Greg Durm retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
FDA approves repotrectinib (Augtyro) for #ROS1 NSCLC based on the phase I/II TRIDENT trial with 1L RR was 79% with mDOR 34.1m and after ROS1 TKI therapy, RR 38% with mDOR 14.8m. Also has activity at #NTRK (which mediates some toxicity). reuters.com/business/healt…
English
0
4
10
1.2K